Table 6 shows the clinical information, including initial and last follow-up of CEA, CA19-9, location of the tumor, mural nodule, enhancement, pathologic result, follow-up period, presence of cholangitis, and presence of malignant change, of non-operative IPNB patients. The gene discussed is CEACAM5; the disease is cholangitis.